HALCION
Clinical safety rating: caution
Comprehensive clinical and safety monograph for HALCION (HALCION).
Triazolam is a benzodiazepine that enhances the effect of GABA at the GABA-A receptor, increasing chloride ion conductance and causing neuronal hyperpolarization, leading to CNS depression.
| Metabolism | Primarily metabolized by CYP3A4 to alpha-hydroxytriazolam and 4-hydroxytriazolam, which are further conjugated and excreted renally. |
| Excretion | Primarily renal (80%) as conjugated metabolites; fecal (8%); unchanged drug <1%. |
| Half-life | Terminal elimination half-life is 1.5–5.5 hours (mean 2.5 hours). Short half-life minimizes next-day sedation. |
| Protein binding | 85–90% bound to albumin. |
| Volume of Distribution | 0.9–1.5 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Oral: 70–100% (mean 80%). |
| Onset of Action | Oral: 15–30 minutes to sleep induction. |
| Duration of Action | Duration of hypnotic effect is 4–6 hours (short-acting), suitable for sleep maintenance with minimal hangover. |
0.25 mg orally once daily at bedtime, maximum 0.5 mg per day.
| Dosage form | TABLET |
| Renal impairment | No specific adjustment recommended; use with caution in severe renal impairment (CrCl <10 mL/min) due to potential accumulation. |
| Liver impairment | Contraindicated in severe hepatic impairment (Child-Pugh class C). In mild to moderate impairment (Child-Pugh A or B), reduce dose by 50% and monitor closely. |
| Pediatric use | Not recommended for use in pediatric patients under 18 years of age due to lack of safety and efficacy data. |
| Geriatric use | Initial dose 0.125 mg orally at bedtime; maximum 0.25 mg per day due to increased sensitivity and risk of falls, cognitive impairment, and residual sedation. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for HALCION (HALCION).
| Breastfeeding | Triazolam is excreted into breast milk in small amounts; the milk-to-plasma ratio is approximately 0.15 to 0.20. Due to the potential for infant sedation, respiratory depression, and withdrawal effects, breastfeeding is not recommended during maternal use of Halcion. Alternative agents are preferred. |
| Teratogenic Risk | Triazolam (Halcion) is a benzodiazepine classified as FDA Pregnancy Category X. First-trimester exposure is associated with an increased risk of congenital malformations, particularly cleft lip and palate. Second and third trimester exposure may cause fetal benzodiazepine syndrome, including hypotonia, lethargy, respiratory depression, and withdrawal symptoms in the neonate. Use is contraindicated during pregnancy. |
■ FDA Black Box Warning
Concomitant use with opioids may result in profound sedation, respiratory depression, coma, and death. Avoid use in patients with severe hepatic impairment.
| Serious Effects |
Hypersensitivity to triazolam or other benzodiazepines, severe hepatic impairment, acute narrow-angle glaucoma, concomitant use with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole), and pregnancy (especially first trimester).
| Precautions | Risk of dependence, tolerance, withdrawal reactions, amnesia, CNS depression, and impaired psychomotor function. Elderly patients at increased risk for falls and cognitive impairment. |
Loading safety data…
| Fetal Monitoring | Regular monitoring of maternal vital signs, sedation level, and respiratory status is advised. In neonates exposed in utero, monitor for signs of respiratory depression, hypotonia, poor feeding, and withdrawal symptoms such as irritability and tremors. |
| Fertility Effects | Benzodiazepines may affect reproductive function by altering hypothalamic-pituitary-adrenal axis and gonadal hormone secretion. In males, there have been reports of decreased libido and erectile dysfunction. In females, menstrual irregularities may occur. Effects on fertility in humans are not well established, but caution is warranted. |